• 7 May, 2024
  Spagos CEO: Advancing the Tumorad programme comes first – BioStock
• 27 Mar, 2024
  Spago Nanomedicals CEO: “huge commercial opportunities are unfolding – BioStock
• 9 Feb, 2024
  Springboard forspagos radionuclide cancer therapy – BioStock
• 15 Jan, 2024
  Spago’s phase I/IIa cancer trial progressing steadily – BioStock
• 20 Dec, 2023
  Positive data in Spago’s phase IIa endometriosis trial – BioStock
• 14 Dec, 2023
  First patient dosed in Spago’s phase I/IIa trial – BioStock
• 30 Oct, 2023
  Tumorads potential in transforming cancer care – BioStock
• 24 Oct, 2023
  Intervju med VD Mats Hansen – Börsvärlden
• 23 Oct, 2023
  Spago Nanomedical’s promising cancer therapy approved for phase I/IIa – BioStock
• 29 Jun, 2023
  Spago Nanomedical’s SAB on Tumorad’s potential – BioStock